MANAGEMENT OF AMD

MANAGEMENT OF AMD
Arthur Cummings
Published: Thursday, August 27, 2015

A dexamethasone intravitreal implant (Ozurdex, Allergan, Inc.) may be a useful adjuvant for decreasing the treatment burden in patients with neovascular age-related macular degeneration (nAMD) persisting or recurring after initial anti-VEGF therapy.

Speaking at the 2015 annual meeting of the Association for Research in Vision and Ophthalmology in Denver, USA, Sandra Rezar MD presented the results of a pilot study conducted by the Vienna Study Centre at the Medical University of Vienna, Austria.

The study enrolled 40 consecutive patients presenting with subretinal and/or intraretinal fluid on optical coherence tomography (OCT) after receiving at least three monthly consecutive injections of ranibizumab (Lucentis, Genentech/Novartis).

They were randomised to receive a dexamethasone implant in combination with ranibizumab or continue anti-VEGF monotherapy and followed monthly. Repeat treatment was based on OCT and visual acuity criteria, and a second dexamethasone implant was allowed no sooner than six months.

During the 12-month study, both groups had stable mean visual acuity and macular sensitivity along with a significant reduction in central retinal thickness. There were no significant differences between groups at 12 months in any of those parameters.

However, time to first retreatment was significantly delayed in the combination group compared with eyes continuing on monotherapy. The difference corresponded to higher rates of complete resolution of macular oedema with the combination therapy. “We know that persistent and recurrent choroidal neovascularisation is common in eyes with nAMD and that persistent exudation leads to reduced visual acuity outcomes,” said Dr Rezar.

As nAMD is a multifactorial disease, monotherapy that focuses selectively on inhibiting angiogenesis may not be optimal. Combination therapy with a corticosteroid addresses the inflammatory component and may help limit VEGF upregulation, she explained.

The mean duration of anti-VEGF treatment prior to enrolment was about 12 months in both groups. The mean number of anti-VEGF injections administered during that period was 5.6 in the eyes randomised to monotherapy and 6.7 in the combination group.

Safety review showed that significant progression of lens opacity occurred in four eyes in the combination group and one eye treated with monotherapy.

“This pilot study showed that combination therapy with dexamethasone and ranibizumab resulted in delay in retreatment while functional parameter could be maintained. Further investigation is needed in order to identify those patients showing greatest benefit from adding corticosteroids to anti-VEGF,” added Dr Rezar.

 

Correspondence – Stefan Sacu: stefan.sacu@meduniwien.ac.at

Sandra Rezar: sandra.rezar@meduniwien.ac.at

Latest Articles
Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

Read more...

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Read more...

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Read more...

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Read more...

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Read more...

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.

Read more...

Matching Premium IOLs to Visual Lifestyles

From monofocal to full-range solutions, each practice needs comprehensive understanding.

Read more...

Going Dutch on Acanthamoeba Keratitis

A world-first trial suggests a new medication could beat the disease.

Read more...

Avoiding Intracorneal Ring Segment Complications

Femtosecond lasers are helping improve refractive results with fewer problems.

Read more...

Fine-Tuning IOLs After Surgery

Lens power adjustment technology is developing quickly.

Read more...